In this study, the results of network pharmacology showed that the key targets of galangin against liver cancer were SRC, ESR1, MMP9, CDK4, CCNB1, MMP2, CDK2, CDK1, CHEK1, and PLK1. The gene discussed is SRC; the disease is liver cancer.